Octreotidum — supply status, manufacturers & alternatives

Octreotidum

—

In supply · Australia

Sandostatin

In supply · 🇦🇺 Australia

In supply in Australia

No active shortage reported.

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Patient information leaflet (PIL)
Active ingredient (INN)	Octreotidum
Brand names	Sandostatin
Therapeutic category	Auto-created by Lyfjastofnun — Tilkynntur lyfjaskortur (Iceland Medicines Agency) scraper
Controlled substance	No

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 8 resolved events

◷

0–1 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🌐

IMA · 1h ago

Resolved

Verified timeline regulator events

🌐 20 Jan 2026

Shortage resolved

🌐 17 Dec 2025

Shortage resolved

🌐 13 Aug 2025

Shortage resolved

🌐 13 June 2025

Shortage resolved

🌐 12 May 2025

Shortage resolved

🌐 29 Mar 2025

Shortage resolved

Sources official regulators

🌐

IMA

verified 1h ago

verify ↗

Mederti Drug Report

Generated 3 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.